基于二硫下垂相关签名改善膀胱癌患者生存和药物敏感性的表格数据

数据集获取（Figshare）

• 源站标题：Table_5_Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.xlsx
• DOI：10.3389/fimmu.2023.1198878.s006
• 发布日期：2023-05-31
• 文件数：1 个
• 文件总体积：10.50 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_5_Leveraging_a_disulfidptosis-based_signature_to_improve_the_survival_and_drug_sensitivity_of_bladder_cancer_patients_xlsx/23268755

命令行下载

curl -L -o "Table_5_Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.xlsx" "https://ndownloader.figshare.com/files/41012009"

文件清单

• Table_5_Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.xlsx（10.50 KB）

文件总体积 10.50 KB（源站 API 实测）。

数据说明

BackgroundDisulfidptosis is a recently discovered form of cell death. However, its biological mechanisms in bladder cancer (BCa) are yet to be understood.
MethodsDisulfidptosis-related clusters were identified by consensus clustering. A disulfidptosis-related gene (DRG) prognostic model was established and verified in various datasets. A series of experiments including qRT-PCR, immunoblotting, IHC, CCK-8, EdU, wound-healing, transwell, dual-luciferase reporter, and ChIP assays were used to study the biological functions.
ResultsWe identified two DRG clusters, which exhibited distinct clinicopathological features, prognosis, and tumor immune microenvironment (TIME) landscapes. A DRG prognostic model with ten features (DCBLD2, JAM3, CSPG4, SCEL, GOLGA8A, CNTN1, APLP1, PTPRR, POU5F1, CTSE) was established and verified in several external datasets in terms of prognosis and immunotherapy response prediction. BCa patients with high DRG scores may be characterized by declined survival, inflamed TIME, and elevated tumor mutation burden. Besides, the correlation between DRG score and immune checkpoint genes and chemoradiotherapy-related genes indicated the implication of the model in personalized therapy. Furthermore, random survival forest analysis was performed to select the top important features within the model: POU5F1 and CTSE. qRT-PCR, immunoblotting, and immunohistochemistry assays showed the enhanced expression of CTSE in BCa tumor tissues. A series of phenotypic assays revealed the oncogenetic roles of CTSE in BCa cells. Mechanically, POU5F1 can transactivate CTSE, promoting BCa cell proliferation and metastasis.
ConclusionsOur study highlighted the disulfidptosis in the regulation of tumor progression, sensitivity to therapy, and survival of BCa patients. POU5F1 and CTSE may be potential therapeutic targets for the clinical treatment of BCa.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2023.1198878.s006（source: https://frontiersin.figshare.com/articles/dataset/Table_5_Leveraging_a_disulfidptosis-based_signature_to_improve_the_survival_and_drug_sensitivity_of_bladder_cancer_patients_xlsx/23268755）。